GI Cancer
Advertisement
Dr. Kimmie Ng shares the experiences that drive her dedication to seeking improved patient outcomes in GI oncology care.
A recent study compared first-line chemotherapy, as the standard of care for PDAC, with other treatment options.
A recent systematic review evaluated the relationship between NLR and the prognosis of patients who receive NAC.
Entinostat has been utilized in other solid tumors for its ability to induce the inhibition of cell proliferation.
Studies of asymptomatic and symptomatic patients have demonstrated lower ctDNA detection in asymptomatic patients.
In several different types of cancer, tumor budding is linked to poor survival outcomes.
The phase III study found that regorafenib improved overall survival in patients with refractory advanced gastric cancer.
Study participants were administered nadunolimab with a standard dose of gemcitabine and nab-paclitaxel (GN) every two weeks.
The SOX chemotherapy regimen for gastric cancer consists of S-1, an oral fluoropyrimidine, in combination with oxaliplatin.
Repeated use of TACE can impair liver function and stimulate tumor angiogenesis.
Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.
Tislelizumab shows significant survival benefits in first-line treatment for gastric and esophageal cancers.
FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.
For postoperative morbidity and mortality, surgery alone had the highest probability rate.
HIMALAYA found tremelimumab plus durvalumab to significantly improve overall survival over sorafenib alone.
Dr. Wungki Park gives an overview of the POLAR study for metastatic pancreatic cancer.
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center discusses his trial on the use of ASP3082 for solid tumors.
While biliary tract cancer is one of the fastest-growing types of early-onset cancers, little is known about its biology.
Little is known about the details of genomic differences and clinical implications between patients with GISTs.
The FAK inhibitor narmafotinib targets solid tumors in pancreatic cancer.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.